Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

AIM AIM ImmunoTech Inc.
$0.25 -2.36% -0.01
Notify me if price changes either direction
Interactive Brokers Logotype

Buy AIM stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 7.1M
Enterprise value 2.6M
Trailing PE -0.028851507296418
Forward PE -0.50576925
PEG Ratio 0.00033475785325022
Enterprise to EBITDA -0.246
Enterprise to revenue 27.844
Price to book MRQ 0.9850188
Price to sales TTM 76.75238

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-03-31
Revenue (TTM) 95000
EBITDA -10734000
Diluted EPS TTM -4.31
Total Cash (MRQ) 10.0M
Current ratio (MRQ) 2.109
Operating Cash Flow (TTM) -14374000

AIM trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent AIM News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.